Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notice reports a proposed sale of 13,389 Class A ordinary shares through Charles Schwab & Co., Inc. on 09/05/2025, with an aggregate market value of $477,497.00. The shares were acquired the same day by employee stock option exercise and the payment method is listed as broker payment for cashless exercise. The filing lists multiple prior sales by the same seller, Eben Tessari, between 06/09/2025 and 09/04/2025, including several larger transactions reported on 06/11/2025, 08/05/2025 and 09/04/2025. Outstanding shares are shown as 43,472,928.
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 notifying a proposed sale of 85,271 Class A ordinary shares through Charles Schwab & Co., Inc. with an aggregate market value of $3,028,740, approximately to be sold on 09/04/2025 on NASDAQ. The shares were acquired the same day via an employee stock option exercise and were settled by a broker payment for a cashless exercise.
The filing also lists insider sales over the past three months by Eben Tessari totaling 381,932 shares across multiple dates with combined gross proceeds of $7,482,197.
Kiniksa Pharmaceuticals International, plc (KNSA) reported a Form 144 notice for a proposed sale of 3,523 Class A ordinary shares through Charles Schwab & Co., with an aggregate market value of $124,397. The filing shows the shares were acquired by restricted stock lapse as equity compensation on 09/01/2025 (3,010 shares) and 09/02/2025 (513 shares). The company’s total outstanding Class A shares are listed as 43,472,928, and the sale is scheduled approximately for 09/04/2025. The notice contains the standard attestations about absence of undisclosed material information and compliance with Rule 144 and Rule 10b5-1 disclosures.
Kiniksa Pharmaceuticals (KNSA) Form 4 — Tessari Eben, Chief Operating Officer. The filing shows multiple equity awards and transactions between September 1–3, 2025. RSUs were granted/recorded totaling 9,828 RSUs on 09/01/2025 and additional RSUs from prior grants are reflected; each RSU converts to one Class A ordinary share. New stock options were granted on 09/01/2025 for 39,364 shares at a $33.49 exercise price and earlier vested options and RSUs remain outstanding. The reporting person sold 15,091 Class A shares on 09/03/2025 at a weighted average price of $35.50 and recorded additional small open-market sales on 09/01–09/02 at $33.49 and $34.28. Post-transactions beneficial ownership totals are reported in the range of 43,438 to 59,543 Class A shares depending on line items.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 reports an intended sale of 15,091 Class A ordinary shares through Charles Schwab & Co., Inc. for an aggregate market value of $535,778, to be traded on NASDAQ approximately on 09/03/2025. The shares were acquired the same day by an employee stock option exercise and the transaction indicates a broker payment for a cashless exercise.
The filing also discloses insider sales by Eben Tessari during the prior three months totaling 261,881 shares for aggregate gross proceeds of $8,341,479 across seven transactions between 06/09/2025 and 08/18/2025. The filing provides specific trade dates, amounts, and proceeds but does not include additional context or reasons for the sales.
Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions from September 1–3, 2025. The filings show a series of restricted share unit (RSU) grants, option exercises and open-market trades executed pursuant to a 10b5-1 plan. On September 3, 2025 the reporting person exercised a share option for 11,000 Class A Ordinary Shares at an exercise price of $17.92 and sold 11,000 shares in the market at a weighted average price of $34.84. Several RSU awards and stock options were granted or recognized on September 1–2, 2025 with various vesting schedules; one option grant has an exercise price of $33.49 and expires August 31, 2035. Following the reported transactions the reporting person beneficially owned 38,011 Class A Ordinary Shares.
Ross Moat, Chief Corporate & Commercial Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions on September 1-2, 2025. The filing shows grant and acquisition of restricted share units (RSUs) and a stock option, and reported dispositions of Class A ordinary shares at prices of $33.49 and $34.28. The derivative section shows an option for 39,364 Class A shares and RSUs representing 9,828 Class A shares, each with specified multi-year vesting schedules. Following the reported transactions, the Form 4 lists beneficial ownership figures for Class A ordinary shares in the range shown, with the last reported post-transaction direct ownership of 12,938 Class A ordinary shares. The filing includes detailed vesting terms: option vesting begins September 1, 2025, and RSUs vest over four-year schedules with 25% annual vesting.
Kiniksa Pharmaceuticals International reported Form 4 transactions for John F. Paolini, its Chief Medical Officer and a director. The filing shows multiple equity award grants and option/RSU issuances on September 1 and 2, 2025, including 9,828 RSUs, a 39,364-share option exercisable through 08/31/2035 at a $33.49 exercise price, and several additional RSU grants tied to prior grant dates. The report also discloses sales of Class A ordinary shares on September 1 (2,841 shares at $33.49) and September 2 (835 shares at $34.28). Post-transactions beneficial ownership totals are shown for each line and all holdings are reported as direct.
Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported multiple equity transactions on Form 4 covering September 1-2, 2025. The filing shows grant activity including 12,275 Restricted Share Units (RSUs), a 39,363-share option with a $33.49 exercise price and several additional RSU grants and awards. It also discloses sales of Class A Ordinary Shares: 2,920 shares sold at $33.49 and 900 shares sold at $34.28. Following the reported transactions, the filing lists varying beneficial ownership totals for each line item, with direct ownership reported for all items. The form is signed by an attorney-in-fact on behalf of the reporting person.
Kiniksa Pharmaceuticals director and Chairman & CEO Sanj K. Patel reported multiple transactions on Form 4 covering September 1-2, 2025. The filing shows grants of 34,435 restricted share units (RSUs), a 137,638-share option with a $33.49 exercise price, and additional RSU grants and deliveries on those dates. The report also discloses open-market disposals: 10,983 Class A shares sold at $33.49 and 3,177 Class A shares sold at $34.28. Following the transactions, Mr. Patel beneficially owns 109,795 shares indirectly held by The Marina 2016 Irrevocable Trust and reports various direct holdings reflected in the table. Vesting schedules are specified: RSUs generally vest over four years with 25% annual vesting and the option vests 25% after one year then monthly over three years.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
